By Mauro Orru

Novartis received approval from the Food and Drug Administration to produce its Pluvicto radioligand therapy at its new manufacturing facility in Indianapolis, expanding capacity to meet growing demand for cancer patients in North America.

The Swiss pharmaceutical company said Friday that the decision from the FDA would lift radioligand therapy production capacity to 250,000 doses in 2024 and beyond. Novartis also has facilities in New Jersey, Italy and Spain.

"Adding a second US RLT facility, our largest and most advanced yet, into our manufacturing network underscores our commitment to ensure a consistent and reliable experience for patients and their healthcare teams for years to come," said Steffen Lang, president of operations. "We also recently announced plans to build our manufacturing capabilities in Sasayama, Japan and Haiyan, Zhejiang, China, as we continue to look for opportunities to further expand our worldwide reach."

Write to Mauro Orru at mauro.orru@wsj.com

(END) Dow Jones Newswires

January 05, 2024 10:00 ET (15:00 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Novartis 차트를 더 보려면 여기를 클릭.
Novartis (NYSE:NVS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Novartis 차트를 더 보려면 여기를 클릭.